---
title: "Teyi Pharmaceutical Group Co.,Ltd. (002728.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002728.SZ.md"
symbol: "002728.SZ"
name: "Teyi Pharmaceutical Group Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T17:25:38.353Z"
locales:
  - [en](https://longbridge.com/en/quote/002728.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002728.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002728.SZ.md)
---

# Teyi Pharmaceutical Group Co.,Ltd. (002728.SZ)

## Company Overview

Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People’s Republic of China. The company’s products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co.,Ltd in November 2016.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.tczy.com.cn](https://www.tczy.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.40)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 50 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.56% |  |
| Net Profit YoY | 76.82% |  |
| P/B Ratio | 2.63 |  |
| Dividend Ratio | 0.51% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4861530240.14 |  |
| Revenue | 838466562.75 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.16% | C |
| Profit Margin | 9.04% | B |
| Gross Margin | 60.99% | A |
| Revenue YoY | 2.56% | C |
| Net Profit YoY | 76.82% | A |
| Total Assets YoY | 4.78% | C |
| Net Assets YoY | 2.71% | C |
| Cash Flow Margin | 219.30% | B |
| OCF YoY | 2.56% | C |
| Turnover | 0.37 | C |
| Gearing Ratio | 20.65% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Teyi Pharmaceutical Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "76.82%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.63",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.51%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4861530240.14",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "838466562.75",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.16%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "9.04%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "60.99%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.56%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "76.82%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.78%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.71%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "219.30%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "2.56%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.65%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 64.21 | 117/215 | 101.90 | 79.43 | 70.77 |
| PB | 2.64 | 123/215 | 3.32 | 2.91 | 2.53 |
| PS (TTM) | 5.80 | 141/215 | 6.49 | 6.02 | 5.36 |
| Dividend Yield | 0.51% | 129/215 | 0.53% | 0.44% | 0.41% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-03-23T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.49 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002728.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002728.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002728.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002728.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**